Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5509602 | Clinica Chimica Acta | 2017 | 30 Pages |
Abstract
The CoaguChek XS and on-site Stago analyzers which used human recombinant (ISI = 1.01) and rabbit brain thromboplastin (ISI = 1.25), respectively, showed reasonable agreement for INR < 3.0 (k = 0.62) but significant difference for INR â¥Â 3.0 (k = 0.10). In contrast, the CoaguChek XS and Siemens BCS XP, which both employed human recombinant thromboplastin (BCS ISI = 1.02), showed greater agreement for the complete range INR values (INR < 3.0 k = 0.84; INR â¥Â 3.0 k = 0.70). ECAA Poller calibrant data showed the automated instruments were performing as expected, indicating that ISI calibrations were correct but insufficient to standardize the INR values for the different thromboplastin methods across the full range of measured INRs. Central lab verification of POCT INR > 5.0 with the Stago Evolution prevented adverse treatment events for the warfarin therapy patients in the six months preceding and following this investigation.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Wendy S. Baker, Kathleen J. Albright, Megan Berman, Heidi Spratt, Peggy A. Mann, Jaime Unabia, John R. Petersen,